Amy T Longcore
Amy T Longcore has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Ritter
Ritter Pharmaceuticals, Inc., Los Angeles, CA 90067, USA
1 shared publication - Dennis A. Savaiano
Purdue University
1 shared publication - Gareth James
University of Southern California
1 shared publication - Howard L Foyt
Ritter Pharmaceuticals, Los Angeles, CA, USA
1 shared publication - Justin R Chandler
Ritter Pharmaceuticals, Los Angeles, CA, USA
1 shared publication - Todd R. Klaenhammer
Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, North Carolina, USA
1 shared publication
Latest Publications
- Open Access
- 13 December 2013
- Published by Springer Nature in Nutrition Journal
- Vol. 12 (1) , 160
Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial
Lactose intolerance (LI) is a common medical problem with limited treatment options. The primary symptoms are abdominal pain, diarrhea, bloating, flatulence, and cramping. Limiting dairy foods to reduce symptoms contributes to low calcium intake and the risk for chronic disease. Adaptation of the colon bacteria to effectively metabolize lactose is a novel and potentially useful approach to improve lactose digestion and tolerance. RP-G28 is novel galacto-oligosaccharide (GOS) being investigated to improve lactose digestion and the symptoms of lactose intolerance in affected patients.
- 13 December 2013
- Published by Springer Nature in Nutrition Journal
- Vol. 12 (1) , 160
Open AccessImproving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial
Lactose intolerance (LI) is a common medical problem with limited treatment options. The primary symptoms are abdominal pain, diarrhea, bloating, flatulence, and cramping. Limiting dairy foods to reduce symptoms contributes to low calcium intake and the risk for chronic disease. Adaptation of the colon bacteria to effectively metabolize lactose is a novel and potentially useful approach to improve lactose digestion and tolerance. RP-G28 is novel galacto-oligosaccharide (GOS) being investigated to improve lactose digestion and the symptoms of lactose intolerance in affected patients.